Mankind Pharma Limited — Results, 17-02-2025: Integrated Filing- Financial

Mankind Pharma Limited has announced a board meeting where the Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024. For Q3, the standalone revenue was ₹2,396.57 crore, with a profit after tax of ₹416.38 crore, reflecting a year-on-year decrease. Debt metrics improved, notably a debt-to-equity ratio of 0.71. Noteworthy is the completion of a ₹3,000 crore QIP, primarily utilized for debt repayment and strategic corporate purposes, indicating a strong liquidity position. Investors may view this as a positive outlook for debt management and operational scalability amid macroeconomic challenges.